Two new treatments, from Viiv Healthcare UK, are able to be prescribed by the NHS in England.
As of today, 14th January 2015, NHS providers in England are able to prescribe Tivicay® (dolutegravir) and Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV-1 infected adults and adolescents aged 12 years or older.
Tivicay is the latest integrase inhibitor to hit the market. Integrase inhibitors work by preventing the viral DNA from integrating into the genetic material of human immune cells. This step is essential in the HIV replication cycleand is also responsible for establishing chronic infection. Triumeq is a once-daily single-pill dolutegravir-based regimen, containing the integrase inhibitor dolutegravir and the nucleoside reverse transcriptase inhibitors abacavir and lamivudine.
Professor Brian Gazzard, Director of HIV/GUM Clinical Research and Education at Chelsea and Westminster Hospital said:
“As HIV has effectively become a long-term condition, we face a new challenge of managing people ageing with HIV and the considerations that presents for long-term quality of life and potential drug-drug interactions. HIV physicians and people living with HIV alike will welcome today’s news that Tivicay and Triumeq are now reimbursed by NHS England. These represent good new treatment options for patients with their favourable efficacy, tolerability and convenience profiles”.
Dr Andrew Benzie, ViiV Healthcare UK Medical Director, added:
“At ViiV Healthcare, our focus is on delivering advances in treatment and care for people living with HIV. I am delighted that both Tivicay and Triumeq are now available in England.”
Availability within England will now depend on the buying decisions of individual NHS Trusts and/or regional pharmaceutical buying groups.
You can view the NHS England Commissioning Policy for Dolutegravir here: http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b06-dolutgvr-trt-hiv.pdf